Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of two amiselimod capsule formulations in healthy males
NCT02310048Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Area under the concentration-time curve up to 6 weeks. Started Nov 2014; status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02310048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310048.